Management of Coagulopathy in Acute-on-Chronic Liver Failure

Introduction to Coagulopathy Management

The American Society of Anesthesiologists recommends that fresh frozen plasma should not be used to correct laboratory coagulation abnormalities in ACLF patients in the absence of active bleeding or planned invasive procedures 1, 2
Standard coagulation tests are poor predictors of bleeding in critically ill patients with advanced liver disease and do not reflect the true hemostatic status of these patients 1
The coagulopathy of liver disease represents a rebalanced hemostatic system, not simply a deficiency state 1

Fresh frozen plasma should be administered when there is active bleeding AND documented coagulopathy (INR >2.0 or PT >1.5 times normal) 2, 3
Use in major hemorrhage protocols, often in 1:1 or 1:1.5 ratio with red blood cells until coagulation results are available 1
Therapeutic dose: 15 ml/kg to achieve minimum 30% concentration of plasma factors 3, 4

FFP transfusion fails to correct PT in non-bleeding patients with mild abnormalities 2
Transfusion-related acute lung injury (TRALI) risk 5
Allergic reactions and infectious disease transmission 5
No evidence that correction of coagulation abnormalities benefits non-bleeding patients 2
Fibrinogen concentrate or cryoprecipitate if fibrinogen <80-100 mg/dL with bleeding 3

Proceed with low-risk procedures without prophylactic FFP correction, as bleeding risk is not predicted by INR elevation alone 1, 2
Reserve FFP for high-risk procedures only when bleeding occurs or patient has additional bleeding risk factors 2

Do not transfuse FFP solely to "normalize" laboratory values - this practice persists despite lack of evidence and exposes patients to unnecessary risks 1, 2
Do not use FFP for volume replacement - it is not indicated for this purpose 1
Do not assume elevated INR equals bleeding risk - the hemostatic balance in liver disease is complex and not captured by standard tests 1